Cell-Free DNA Sequencing Reveals Gene Variants in DNA Damage Repair Genes Associated with Prognosis of Prostate Cancer Patients
Authors:
- Verena LiebVLVerena Lieb
- Amer AbdulrahmanAmer Abdulrahman
- Katrin WeigeltKWKatrin Weigelt
- Siegfried HauchSHSiegfried Hauch
- Michael GombertMGMichael Gombert
- Juan GuzmanJGJuan Guzman
- Laura BellutLBLaura Bellut
- Peter J. GoebellPGPeter J. Goebell
- Robert StöhrRobert Stöhr
- Arndt HartmannArndt Hartmann
- Bernd WullichBWBernd Wullich
- Helge TaubertHelge Taubert
Open Access
Abstract
In the present study, we further analyzed the data obtained in our previous study, where we investigated the cell-free DNA (cfDNA) of 34 progressive prostate cancer patients via targeted sequencing. Here, we studied the occurrence and prognostic impact of sequence variants according to their clinical pathological significance (CPS) or their functional impact (FI) in 23 DNA damage repair (DDR) genes with a focus on the ATM serine/threonine kinase gene (ATM). All patients had at least one DDR gene with a CPS or FI variant. Kaplan-Meier analysis indicated that the group with a higher number of CPS variants in DDR genes had a shorter time to treatment change (TTC) compared to the group with a lower number of CPS variants (p = 0.038). Analysis of each DDR gene revealed that CPS variants in the ATM gene and FI variants in the nibrin (NBN) gene showed a shorter TTC (p = 0.034 and p = 0.042). In addition, patients with CPS variants in the ATM gene had shorter overall survival (OS; p = 0.022) and disease-specific survival (DSS; p = 0.010) than patients without these variants. Interestingly, patients with CPS variants in seven DDR genes possessed a better OS (p = 0.008) and DSS (p = 0.009), and patients with FI variants in four DDR genes showed a better OS (p = 0.007) and DSS (p = 0.008). Together, these findings demonstrated that the analysis of cfDNA for gene variants in DDR genes provides prognostic information that may be helpful for future temporal and targeted treatment decisions for advanced PCa patients.Keywords
Funding Information
- Verein zur Förderung des Tumorzentrums der Universität Erlangen-Nürnberg e.V. (TA 145/17-1, 2015.171.1, 14-07-11-1-Huppert)
- Deutsche Forschungsgemeinschaft (TA 145/17-1, 2015.171.1, 14-07-11-1-Huppert)
- Rudolf and Irmgard Kleinknecht-Stiftung (TA 145/17-1, 2015.171.1, 14-07-11-1-Huppert)
- Wilhelm Sander-Stiftung (TA 145/17-1, 2015.171.1, 14-07-11-1-Huppert)
- Deutsche Gesellschaft für Urologie (TA 145/17-1, 2015.171.1, 14-07-11-1-Huppert)
This publication has 53 references indexed in Scilit:
- Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patientsTumor Biology, 2013
- Punctuated Evolution of Prostate Cancer GenomesCell, 2013
- Inactivation of ATM/ATR DNA Damage Checkpoint Promotes Androgen Induced Chromosomal Instability in Prostate Epithelial CellsPLOS ONE, 2012
- The genomic landscape of prostate cancerFrontiers in Endocrinology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer DevelopmentCell, 2011
- Diagnostic Role of Circulating Free Plasma DNA Detection in Patients With Localized Prostate CancerAmerican Journal of Clinical Pathology, 2008
- Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicatorsInternational Journal of Cancer, 2007
- DNA damage response as a candidate anti-cancer barrier in early human tumorigenesisNature, 2005
- Role of Cell‐Free Plasma DNA as a Diagnostic Marker for Prostate CancerAnnals of the New York Academy of Sciences, 2004